Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07268638 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | PHASE2 | RECRUITING | 60 | — | — | Dec 3, 2025 | Jan 1, 2028 | Jun 5, 2026 | 14 | United States |
| Arm | Type | Description |
|---|---|---|
| Praliciguat | EXPERIMENTAL | Praliciguat will be administered daily with dose escalation to a target dose during a 24-week double-blind period, followed by a 24-week open-label treatment period. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo will be administered daily for 24 weeks |
| Name | Type | Description |
|---|---|---|
| Praliciguat | DRUG | Oral Tablet |
| Placebo | OTHER | Oral Tablet |
Inclusion Criteria: 1. UPCR ≥1 (g/g) during screening. 2. On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent. 3. Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Col...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL2 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | frexalimab, brivekimig, rilzabrutinib |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| Akebia Therapeutics, Inc. | AKBA | 1 | PHASE2 | Praliciguat |
| Travere Therapeutics, Inc. | TVTX | 1 | PHASE2 | Sparsentan |
| Vera Therapeutics, Inc. Class A | VERA | 1 | PHASE2 | Atacicept |